BiotechTube
BioVersys

BioVersys

Basel, Switzerland· Est.
bioversys.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

BioVersys is a privately held, clinical-stage biopharmaceutical company dedicated to addressing the global threat of antimicrobial resistance (AMR). Its pipeline features innovative, first-in-class assets with novel modes of action, targeting WHO and CDC priority pathogens like carbapenem-resistant Acinetobacter baumannii (CRAB) and Staphylococcus aureus. Key programs include BV100, which is entering Phase 3 for CRAB infections, and Alpibectir, a potentiator for MDR-TB treatment currently in Phase 2b. The company operates from its Basel headquarters, leveraging a platform focused on transcriptional regulator inhibitory compounds (TRIC) to develop impactful anti-infectives.

Infectious DiseaseAntimicrobial ResistanceTuberculosis

Technology Platform

Transcriptional Regulator Inhibitory Compounds (TRIC) platform for developing novel small molecules with anti-virulence, resistance-potentiating, and direct antibacterial mechanisms of action.

Funding History

7
Total raised:$105M
Grant$5M
Series C$25M
Series C$20M
Series B$20M

Opportunities

The massive and growing global burden of AMR, underscored by WHO/CDC priority pathogen lists, creates a pressing need for new therapies.
Successful clinical development of its novel-mechanism assets could position BioVersys for strategic partnerships, acquisition, or leadership in a high-need therapeutic area with increasing regulatory and funding incentives.

Risk Factors

High risk of clinical trial failure for its lead assets.
The anti-infective market presents severe commercialization challenges, including pricing, stewardship, and potentially low sales volumes.
As a pre-revenue company, it remains dependent on raising capital in a volatile financing environment.

Competitive Landscape

BioVersys competes in the novel antibiotic space with other small biotechs and large pharma, targeting high-priority pathogens. Its differentiation lies in its TRIC platform and novel mechanisms (potentiation, anti-virulence). Competition is intense for funding and partnerships, but the unmet medical need is large enough to support multiple successful entrants.

More companies in Small Molecule Drugs →More companies in Switzerland →